See more : Toin Corporation (7923.T) Income Statement Analysis – Financial Results
Complete financial analysis of Helix BioPharma Corp. (HBPCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Helix BioPharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cargotrans Maritime Limited (CARGOTRANS.BO) Income Statement Analysis – Financial Results
- Shanshan Brand Management Co., Ltd. (1749.HK) Income Statement Analysis – Financial Results
- Dynapack International Technology Corporation (3211.TWO) Income Statement Analysis – Financial Results
- Gish International Co., Ltd (8067.TWO) Income Statement Analysis – Financial Results
- Vasudhagama Enterprises Limite (VASUDHAGAM.BO) Income Statement Analysis – Financial Results
Helix BioPharma Corp. (HBPCF)
About Helix BioPharma Corp.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.26M | 4.53M | 4.43M | 3.84M | 3.59M | 3.42M |
| Cost of Revenue | 13.00K | 12.00K | 173.00K | 212.00K | 56.00K | 167.00K | 130.00K | 134.00K | 0.00 | 0.00 | 0.00 | 1.74M | 1.64M | 1.67M | 1.52M | 1.24M | 1.14M |
| Gross Profit | -13.00K | -12.00K | -173.00K | -212.00K | -56.00K | -167.00K | -130.00K | -134.00K | 0.00 | 0.00 | 0.00 | 2.52M | 2.89M | 2.77M | 2.33M | 2.35M | 2.29M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.13% | 63.77% | 62.36% | 60.53% | 65.50% | 66.73% |
| Research & Development | 5.28M | 4.54M | 5.88M | 5.87M | 5.01M | 6.08M | 7.06M | 5.82M | 4.89M | 5.24M | 5.03M | 7.45M | 7.32M | 10.72M | 10.32M | 5.06M | 4.12M |
| General & Administrative | 299.00K | 595.00K | 3.25M | 2.72M | 2.47M | 2.44M | 3.21M | 3.84M | 3.89M | 3.50M | 3.20M | 4.58M | 6.52M | 4.45M | 4.94M | 4.80M | 4.47M |
| Selling & Marketing | 746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09M | 1.12M | 1.13M | 969.00K | 0.00 | 0.00 |
| SG&A | 1.05M | 595.00K | 3.25M | 2.72M | 2.47M | 2.44M | 3.21M | 3.84M | 3.89M | 3.50M | 3.20M | 5.67M | 7.64M | 5.58M | 5.91M | 4.80M | 4.47M |
| Other Expenses | -59.00K | -501.00K | -142.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.33M | 6.04M | 9.13M | 8.62M | 7.49M | 8.55M | 10.26M | 9.66M | 8.78M | 8.74M | 8.23M | 13.12M | 15.37M | 16.67M | 16.62M | 10.14M | 10.36M |
| Cost & Expenses | 6.33M | 6.04M | 9.13M | 8.62M | 7.49M | 8.55M | 10.26M | 9.66M | 8.78M | 8.74M | 8.23M | 14.86M | 17.01M | 18.34M | 18.13M | 11.37M | 11.50M |
| Interest Income | 47.00K | 4.00K | 0.00 | 25.00K | 3.00K | 9.00K | 16.00K | 26.00K | 56.00K | 43.00K | 50.00K | 125.00K | 188.00K | 49.00K | 339.00K | 645.00K | 496.00K |
| Interest Expense | 14.00K | 18.00K | 15.00K | 25.00K | 1.00K | 29.00K | 14.00K | 17.00K | 13.00K | 19.00K | 25.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 13.00K | 12.00K | 199.00K | 211.00K | 125.00K | 165.00K | 130.00K | 134.00K | 133.00K | 232.00K | 396.00K | 699.00K | 404.00K | 429.00K | 286.00K | 270.00K | 446.00K |
| EBITDA | -6.31M | -6.53M | -9.07M | -8.38M | -6.72M | -8.38M | -10.12M | -9.52M | -8.64M | -8.46M | -7.78M | -9.78M | -10.61M | -13.53M | -13.91M | -7.51M | -6.31M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -229.46% | -294.53% | -291.27% | -358.58% | -218.32% | -184.14% |
| Operating Income | -6.33M | -6.54M | -9.61M | -8.59M | -7.49M | -8.54M | -10.25M | -9.63M | -8.72M | -8.69M | -8.18M | -17.46M | -12.48M | -13.34M | -14.06M | -8.11M | -6.75M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -409.74% | -275.31% | -300.95% | -366.02% | -225.84% | -197.17% |
| Total Other Income/Expenses | 36.00K | -523.00K | -443.00K | 55.00K | -32.00K | -79.00K | 35.00K | -8.00K | -3.00K | 53.00K | 16.00K | 32.00K | 1.46M | -468.00K | -25.00K | 972.00K | 505.00K |
| Income Before Tax | -6.29M | -6.56M | -9.57M | -8.56M | -7.53M | -8.63M | -10.06M | -9.67M | -8.78M | -8.68M | -8.19M | -17.42M | -11.01M | -14.42M | -14.08M | -6.81M | -7.57M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -408.99% | -243.03% | -325.28% | -366.68% | -189.67% | -221.06% |
| Income Tax Expense | 0.00 | -484.00K | -1.66M | 449.00K | 1.00K | 29.00K | 14.00K | 17.00K | -37.00K | 19.00K | -6.62M | 17.00K | 334.00K | 46.00K | 18.00K | 153.00K | 105.00K |
| Net Income | -6.29M | -6.56M | -8.04M | -8.99M | -7.53M | -8.63M | -10.06M | -9.67M | -8.73M | -8.68M | -1.55M | -17.42M | -11.35M | -14.47M | -14.10M | -6.96M | -7.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -408.99% | -250.40% | -326.32% | -367.14% | -193.93% | -224.12% |
| EPS | -0.03 | -0.04 | -0.06 | -0.07 | -0.07 | -0.09 | -0.11 | -0.11 | -0.11 | -0.12 | -0.02 | -0.26 | -0.17 | -0.24 | -0.27 | -0.16 | -0.22 |
| EPS Diluted | -0.03 | -0.04 | -0.06 | -0.07 | -0.07 | -0.09 | -0.11 | -0.11 | -0.11 | -0.12 | -0.02 | -0.26 | -0.17 | -0.24 | -0.27 | -0.16 | -0.22 |
| Weighted Avg Shares Out | 193.23M | 149.49M | 137.89M | 127.71M | 106.65M | 99.93M | 91.80M | 85.55M | 78.59M | 70.96M | 67.23M | 67.21M | 65.32M | 59.12M | 52.00M | 42.47M | 35.62M |
| Weighted Avg Shares Out (Dil) | 193.23M | 149.49M | 137.89M | 127.71M | 106.65M | 99.93M | 91.80M | 85.55M | 78.59M | 70.96M | 67.23M | 67.21M | 65.32M | 59.12M | 52.00M | 42.47M | 35.62M |
Helix BioPharma releases 1Q results as it works on developing roadmap for lung cancer drug by 2Q 2023
Helix BioPharma Corp. (TSX:HBP) has announced its financial results for its fiscal first quarter ended October 31, 2022. In addition to the results, the company also announced developments in LDOS47 in lung cancer therapy and LDOS47 in pancreatic cancer.
Helix BioPharma appoints Jacek Antas as CEO to replace Artur Gabor with immediate effect
Helix BioPharma Corp. (TSX:HBP) has announced the appointment of Jacek Antas as the company's chief executive officer (CEO) to replace Artur Gabor with immediate effect. It said Gabor has resigned as the CEO and a director of the board of...
Helix BioPharma closes private placement financing for net proceeds of C$4,629,019.86
Helix BioPharma Corp. (TSX:HBP) said it has closed a private placement financing for net proceeds of C$4,629,019.86 from the issuance of 25,716,777 common shares at a price of $0.18 each. The company said it intends to use the net proceeds...
Helix BioPharma advances clinical development of lead candidate L-DOS47, but manages to decrease R&D expenses in 2022 fiscal year
Helix BioPharma Corp. (TSX:HBP), focused on trying to combat killer cancers based on its DOS47 technological platform, reported that it advanced the development of its lead candidate L-DOS47, which is currently in clinical studies for lung and pancreatic cancer, while...
Helix BioPharma appoints Dr. Frank Gary Renshaw as Chief Medical Officer
Helix BioPharma Corp. (TSX:HBP) said it has appointed Dr. Frank Gary Renshaw as its Chief Medical Officer.
Helix BioPharma Corp names Dr Gabrielle Siegers as its head of research and development
Helix BioPharma Corp. (TSX:HBP) has announced the appointment of Dr Gabrielle Siegers as its head of research and development based out of the company's lab in Edmonton. Dr Siegers comes to Helix from IN8bio, a US biotech company developing Gamma...
Helix BioPharma announces scientific collaboration with University Hospital Tuebingen in Germany
Helix BioPharma Corp. (TSX:HBP) said it has entered into a two-year scientific collaboration agreement with University Hospital Tuebingen in Germany to assess the therapeutic response of its lead candidate L-DOS47 in several cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. ...
Helix BioPharma closes private placement financing for net proceeds of $2,002,000 with shareholder Jerzy Wilczewski
Helix BioPharma Corp said it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common share. The company noted that Jerzy Wilczewski, an insider of...
Helix BioPharma appoints Artur Gabor as its new CEO; adds three new board members
Helix BioPharma Corp announced the appointment of Artur Gabor as the company's new permanent CEO, effective immediately. The clinical-stage biopharmaceutical company also said it has added Jerzy Leszczyński, Christopher Maciejewski, and Jacek Antas as new members to its board of directors.
Helix BioPharma announces sudden passing of interim CEO Slawomir Majewski
Helix BioPharma Corp. (TSX:HBP) interim CEO and board chairman Slawomir Majewski has passed away suddenly, the biopharmaceutical company said “with great sadness”. Majewski served on the board since 2012 and took over the CEO in an interim capacity since September 2021.
Source: https://incomestatements.info
Category: Stock Reports